These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25317574)

  • 21. Medication safety: opening up the black box.
    Mintzes B
    BMJ Qual Saf; 2013 Sep; 22(9):702-4. PubMed ID: 23832923
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
    Drozda K; Müller DJ; Bishop JR
    Pharmacotherapy; 2014 Feb; 34(2):166-84. PubMed ID: 24523097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Special Interest Group-Sponsored Update in Psychosomatics: Food and Drug Administration Revises Pregnancy and Lactation Drug Labeling.
    Dresner N; Sachdeva J
    Psychosomatics; 2016; 57(4):439-40. PubMed ID: 27283251
    [No Abstract]   [Full Text] [Related]  

  • 24. A Patient-Centered Prescription Drug Label to Promote Appropriate Medication Use and Adherence.
    Wolf MS; Davis TC; Curtis LM; Bailey SC; Knox JP; Bergeron A; Abbet M; Shrank WH; Parker RM; Wood AJ
    J Gen Intern Med; 2016 Dec; 31(12):1482-1489. PubMed ID: 27542666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving patient understanding of prescription drug label instructions.
    Davis TC; Federman AD; Bass PF; Jackson RH; Middlebrooks M; Parker RM; Wolf MS
    J Gen Intern Med; 2009 Jan; 24(1):57-62. PubMed ID: 18979142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Issues and Future Trends Impacting Drug Safety in South Korea.
    Kim MG; Huh S; Han N; Kim JH; Kim K; Lee E; Kim IW; Oh JM
    Int J Environ Res Public Health; 2019 Sep; 16(18):. PubMed ID: 31547245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safe & sound. Interview by Helena Gail Rubinstein.
    Woodcock J
    AHIP Cover; 2009; 50(2):38-43. PubMed ID: 19385317
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and regulatory considerations in pharmacogenetic testing.
    Schuck RN; Marek E; Rogers H; Pacanowski M
    Am J Health Syst Pharm; 2016 Dec; 73(23):1999-2006. PubMed ID: 27864207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.
    Whirl-Carrillo M; Huddart R; Gong L; Sangkuhl K; Thorn CF; Whaley R; Klein TE
    Clin Pharmacol Ther; 2021 Sep; 110(3):563-572. PubMed ID: 34216021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancing prescription drug innovation and adoption.
    Alexander GC; O'Connor AB; Stafford RS
    Ann Intern Med; 2011 Jun; 154(12):833-7, W-301. PubMed ID: 21690598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing.
    Haga SB; Moaddeb J
    Pharmacogenomics; 2015; 16(4):299-301. PubMed ID: 25823778
    [No Abstract]   [Full Text] [Related]  

  • 33. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
    Pai SA; Kshirsagar N
    J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tall Man lettering and potential prescription errors: a time series analysis of 42 children's hospitals in the USA over 9 years.
    Zhong W; Feinstein JA; Patel NS; Dai D; Feudtner C
    BMJ Qual Saf; 2016 Apr; 25(4):233-40. PubMed ID: 26534995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suitability of common drugs for patients who avoid animal products.
    Tatham KC; Patel KP
    BMJ; 2014 Feb; 348():g401. PubMed ID: 24496281
    [No Abstract]   [Full Text] [Related]  

  • 36. Primary care physicians' use of FDA-approved prescription drug labels.
    Sullivan HW; O'Donoghue AC; Aikin KJ
    J Am Board Fam Med; 2014; 27(5):694-8. PubMed ID: 25201939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACMT Position Statement: Safety Issues Regarding Prescription Fentanyl Products.
    American College of Medical Toxicology
    J Med Toxicol; 2016 Jun; 12(2):211-2. PubMed ID: 26847376
    [No Abstract]   [Full Text] [Related]  

  • 38. Insomnia From Drug Treatments: Evidence From Meta-analyses of Randomized Trials and Concordance With Prescribing Information.
    Doufas AG; Panagiotou OA; Panousis P; Wong SS; Ioannidis JP
    Mayo Clin Proc; 2017 Jan; 92(1):72-87. PubMed ID: 27842706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proposed US Food and Drug Administration guidance for industry on distributing medical publications about the risks of prescription drugs and biological products: a misguided approach.
    Wolfe SM
    JAMA Intern Med; 2014 Oct; 174(10):1543-4. PubMed ID: 25127222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.